AU2001278610A1 - Pharmaceutical compositions comprising a modulator of adamts-1 - Google Patents

Pharmaceutical compositions comprising a modulator of adamts-1

Info

Publication number
AU2001278610A1
AU2001278610A1 AU2001278610A AU7861001A AU2001278610A1 AU 2001278610 A1 AU2001278610 A1 AU 2001278610A1 AU 2001278610 A AU2001278610 A AU 2001278610A AU 7861001 A AU7861001 A AU 7861001A AU 2001278610 A1 AU2001278610 A1 AU 2001278610A1
Authority
AU
Australia
Prior art keywords
adamts
modulator
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278610A
Inventor
Anders Thelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2001278610A1 publication Critical patent/AU2001278610A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
AU2001278610A 2000-08-22 2001-08-16 Pharmaceutical compositions comprising a modulator of adamts-1 Abandoned AU2001278610A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0002973A SE0002973D0 (en) 2000-08-22 2000-08-22 Method
SE0002973 2000-08-22
PCT/GB2001/003650 WO2002016632A1 (en) 2000-08-22 2001-08-16 Pharmaceutical compositions comprising a modulator of adamts-1

Publications (1)

Publication Number Publication Date
AU2001278610A1 true AU2001278610A1 (en) 2002-03-04

Family

ID=20280755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278610A Abandoned AU2001278610A1 (en) 2000-08-22 2001-08-16 Pharmaceutical compositions comprising a modulator of adamts-1

Country Status (7)

Country Link
US (1) US20040014636A1 (en)
EP (1) EP1313874A1 (en)
JP (1) JP2004507468A (en)
AU (1) AU2001278610A1 (en)
GB (1) GB2381000A (en)
SE (1) SE0002973D0 (en)
WO (1) WO2002016632A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305811A1 (en) * 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
WO2007147497A2 (en) * 2006-06-17 2007-12-27 Bayer Healthcare Ag Use of a disintegrin-like and metalloproteinase with thrombospondin type 1 motif (adamts1) as a therapeutic or diagnostic target
JP5809205B2 (en) * 2013-07-16 2015-11-10 国立大学法人 東京大学 Osteoporosis susceptibility gene and method for measuring osteoporosis risk

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0874050A3 (en) * 1997-04-24 2002-06-05 Smithkline Beecham Corporation Integrin ligand ITGL-TSP
US6565858B2 (en) * 1997-06-03 2003-05-20 Kureha Chemical Industry Co., Ltd. Human ADAMTS-1 protein and pharmaceutical composition

Also Published As

Publication number Publication date
WO2002016632A1 (en) 2002-02-28
JP2004507468A (en) 2004-03-11
GB0301654D0 (en) 2003-02-26
GB2381000A (en) 2003-04-23
US20040014636A1 (en) 2004-01-22
EP1313874A1 (en) 2003-05-28
SE0002973D0 (en) 2000-08-22

Similar Documents

Publication Publication Date Title
AU781269C (en) Pharmaceutical compositions
AU2001250420A1 (en) Pharmaceutical compositions
AU2001224716A1 (en) A medicinal aerosol formulation
AU2001274307A1 (en) Pharmaceutical compositions
AU2001226233A1 (en) A medicinal aerosol formulation
AU2001276934A1 (en) Methods of modulating fibrosis
AU2002212254A1 (en) Microcapsule powder
AU2001265933A1 (en) Compounds with a sulphonamide group and pharmaceutical compositions containing these compounds
AU2002217464A1 (en) Medicinal compositions containing aspirin
AU2001271037A1 (en) Pharmaceutical compositions containing dds compounds
HUP0201591A2 (en) Pharmaceutical formulations comprising an hiv protease inhibitor
AU2002214324A1 (en) Medicinal compositions
AU2001266084A1 (en) Pharmaceutical preparations comprising racecadotril (acetorphan)
AU2001224718A1 (en) A medicinal aerosol formulation
AU2001273919A1 (en) Pharmaceutical compositions
AU2002231656A1 (en) Assembly comprising a plurality of mask containers
AU2001259318A1 (en) A medicinal aerosol formulation
PL369268A1 (en) A stable pharmaceutical composition of pravastatin
AU2001278610A1 (en) Pharmaceutical compositions comprising a modulator of adamts-1
AU4085201A (en) Pharmaceutical composition
AU2002246659A1 (en) Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
AU2001227531A1 (en) A medicinal aerosol formulation
AU2001247123A1 (en) A medicinal aerosol formulation
AU2001288325A1 (en) Pharmaceutical compounds useful as modulators of endocannabinoid-mediated response
AU2001278705A1 (en) Pharmaceutical composition